Abbott, Mead Johnson secure win in infant formula trial, Reuters reports
The Fly

Abbott, Mead Johnson secure win in infant formula trial, Reuters reports

Abbott (ABT) and Reckitt Benckiser’s (RBGLY) unit Mead Johnson are not responsible for a young boy’s debilitating intestinal disease, a jury found on Thursday, reported Reuters. The ruling in the lawsuit that accused the companies of failing to warn of the risks of premature baby formulas is a victory for the companies following large losses in similar trials, notes the report. Shares of both parent companies’ stocks are trading higher on Friday following the ruling.

Don't Miss out on Research Tools:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App